Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 264 results for carcinoma

  1. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

  2. Cryotherapy for recurrent prostate cancer (HTG71)

    Evidence-based recommendations on cryotherapy for treating recurrent prostate cancer. This involves putting special needles or probes into the prostate and using Argon gas to freeze and destroy the cancerous prostate tissue.

  3. Laparoscopic liver resection (HTG83)

    Evidence-based recommendations on laparoscopic liver resection. This involves making small incisions (keyhole surgery) to remove the parts of the liver that are benign or cancerous.

  4. Elafibranor for previously treated primary biliary cholangitis (TA1016)

    Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.

  5. Laparoscopic deroofing of simple renal cysts (HTG145)

    Evidence-based recommendations on laparoscopic deroofing of simple renal cysts. This involves draining the cyst and removing part of the cyst wall through small cuts in the abdomen (keyhole surgery).

  6. Minimally invasive video-assisted thyroidectomy (HTG349)

    Evidence-based recommendations on minimally invasive video-assisted thyroidectomy. This involves inserting instruments through a small cut (keyhole surgery) to remove part or all of the gland.

  7. Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]

    Discontinued Reference number: GID-TA10830

  8. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued Reference number: GID-TA10321

  9. Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

    Discontinued Reference number: GID-TA10811

  10. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued Reference number: GID-TA11240

  11. Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]

    In development Reference number: GID-TA11767 Expected publication date:  04 November 2026

  12. High-intensity focused ultrasound for prostate cancer (HTG70)

    Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.

  13. Irreversible electroporation for treating renal cancer (HTG303)

    Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.

  14. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued Reference number: GID-TA10259

  15. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued Reference number: GID-TA11041